We previously defined eight groups of monoclonal antibodies which react with distinct epitopes of herpes simplex virus glycoprotein D (gD). One of these, group VII antibody, was shown to react with a type-common continuous epitope within residues 11 to 19 of the mature glycoprotein (residues 36 to 44 of the predicted sequence of gD). In the current investigation, we have localized the sites of binding of two additional antibody groups which recognize continuous epitopes of gD. Glycoprotein D (gD) of herpes simplex virus (HSV) is a structural component of the virion envelope which stimulates production of high titers of virus-neutralizing activity (7, 9, 11, (15) (16) (17) 34) and is likely to play an important role in the initial stages of viral infection. It was recently shown that anti-gD antibodies can block the fusion of infected cells (39). In addition, mice immunized with gD are protected from a lethal HSV challenge (4, 30, 34, 40) . Tryptic peptide analysis (2, 16) and amino-terminal sequencing (14) showed that gD of HSV type 2 (HSV-2) (gD-2) is structurally similar though not identical to gD of HSV-1 (gD-1). Recently, the genes for gD-1 and gD-2 were localized and sequenced (29, 32, 50, 51) . Although the deduced amino acid sequences for the two glycoproteins were shown to be 85% homologous, little is known about the secondary or tertiary structure of these two proteins. Using monoclonal antibodies (MCAb), we previously defined eight epitopes within gD (15), some of which are type common and others of which are type specific. Our goal is to relate the structure of the protein to its biological functions. The high degree of amino acid sequence homology between gD-1 and gD-2 probably accounts for the immunological cross-reactivity of polyclonal antibodies and MCAb directed against gD (15, 41) . On the other hand, the type specificity of other MCAb is undoubtedly related to differences in the structures of gD-1 and gD-2 and, consequently, in amino acid sequence.
Glycoprotein D (gD) of herpes simplex virus (HSV) is a structural component of the virion envelope which stimulates production of high titers of virus-neutralizing activity (7, 9, 11, (15) (16) (17) 34) and is likely to play an important role in the initial stages of viral infection. It was recently shown that anti-gD antibodies can block the fusion of infected cells (39) . In addition, mice immunized with gD are protected from a lethal HSV challenge (4, 30, 34, 40) . Tryptic peptide analysis (2, 16) and amino-terminal sequencing (14) showed that gD of HSV type 2 (HSV-2) (gD-2) is structurally similar though not identical to gD of HSV-1 (gD-1). Recently, the genes for gD-1 and gD-2 were localized and sequenced (29, 32, 50, 51) . Although the deduced amino acid sequences for the two glycoproteins were shown to be 85% homologous, little is known about the secondary or tertiary structure of these two proteins. Using monoclonal antibodies (MCAb), we previously defined eight epitopes within gD (15) , some of which are type common and others of which are type specific. Our goal is to relate the structure of the protein to its biological functions. The high degree of amino acid sequence homology between gD-1 and gD-2 probably accounts for the immunological cross-reactivity of polyclonal antibodies and MCAb directed against gD (15, 41) . On the other hand, the type specificity of other MCAb is undoubtedly related to differences in the structures of gD-1 and gD-2 and, consequently, in amino acid sequence.
EPITOPES OF HSV-1 gD 635 MATERIALS AND METHODS Cells, virus, and radioactive labeling procedures. Conditions for the growth and maintenance of BHK and KB cells and for the propagation of virus have been described (8, 11) . For infection, an input multiplicity of 20 PFU of HSV-1 (HF) and 10 PFU of HSV-2 (Savage) per cell was used. Procedures for labeling of HSV-infected cells with [35S] methionine (specific activity, 600 Ci/mmol) (Amersham Corp.) and [2,3- 3H]arginine (specific activity, 15 Ci/mmol) (Amersham) have been described previously (9, 13, 15, 16) .
Preparation of polyclonal antibody and MCAb to gD. Anti-gD-1 and anti-gD-2 sera were prepared in rabbits against immunosorbant-purified preparations of gD-1 and gD-2 (17) .
MCAb HD-1 (group I) and MCAb 170 (group VII) were supplied by L. Pereira (15, 41) . MCAb 55S and 57S (group V), 11S (group III), 41S (group IV), and 45S (group VI) were supplied by M. Zweig (48) . MCAb DL6 (group II) was prepared from mice immunized intraperitoneally (34) with 6 ,ug of immunosorbant-purified gD-1 (17) . Three days after an intravenous boost of 1 jig, the spleen was removed and the cells were fused to SP2/0 cells by the procedure of McKearn (28) . Hybridomas were cloned in soft agarose (25) , and ascites fluids were prepared from Pristane-primed mice immunized intraperitoneally with cloned cells.
To prepare immunosorbants, immunoglobulin G (IgG) was purified from ascites fluids of MCAb from each group (15) and linked to cyanogen bromide-activated Sepharose 4B (Pharmacia Fine Chemicals, Inc.). The amounts coupled ranged from 5 to 12 mg of IgG per g of Sepharose. Purified immunoglobulins (50 Rxg) were iodinated with 1251 (Amersham) by either the chloramine-T (19) or the lactoperoxidase (36) method. For certain MCAb, the chloramine-T method inactivated the binding activity of the antibody. Group IV MCAb were inactivated by both procedures.
Synthetic peptides. Synthetic peptides to residues 1 to 23 of gD-1 (1-23 [1] ) and gD-2 (1-23 [2] ) were prepared as described previously (7) . The peptides representing residues 340 to 356 of gD-1 (340-356 [1] ) and 268 to 287 of gD-1 (268-287 [1] ) were prepared by Peninsula Laboratories, Inc. Cysteine was added to the amino terminus of 340-356 [1] and to the carboxy terminus of 268-287 [1] . The procedures for coupling of peptides to keyhole limpet hemocyanin (KLH) were described previously (7, 33) . Briefly, the maleimide group of the peptide was incorporated into KLH with M-malimidobenzol-N-hydroxysuccinimide ester and the M-malimidobenzol-N-hydroxysuccinimide ester-modified proteins were allowed to react with a 20 M excess of the peptide (22) . The coupling ratio of peptide/carrier was previously determined to be 8 (7) . All (ii) Truncated gD-1, residues 1 to 275. The gene for gD-1 was cloned into a pBR322-simian virus 40 shuttle vector and included a DNA fragment from a HindlIl site upstream of the gD gene to a Hinfl site at residue 300 of the predicted gD-1 sequence (residue 275 of the mature protein). When this plasmid is grown in Chinese hamster ovary cells, the glycoprotein is secreted (30) . The glycoprotein was purified by affinity chromatography, using a gD-specific MCAb (17) .
(iii) Truncated gD- Immunoblot and neutralization assays. The immunoblot assay was done as previously described (7, 20) , using antisera or MCAb and iodinated protein A (Amersham). Virus neutralization assays (50% plaque reduction method), using HSV-1 (HF) or HSV-2 (Savage), were carried out as previously described (9, 11) .
Competition assays. Two competition assays were used. (i) Immunosorbants. A total of 100 to 200 ,ul (representing 150 to 600 ,ug of IgG) of MCAb linked to Sepharose was incubated for 2 h at 37°C with 100 ,ul of a cytoplasmic extract of unlabeled HSV-1-infected cells (9, 13, 15, 16) . The immunosorbant was washed 10 times with washing buffer, and the iodinated second antibody (at least 250,000 cpm) was added. The complex was washed exhaustively and counted in a gamma counter.
(ii) Nitrocellulose. Purified gD-1 (0.45 to 15 ng) was spotted onto nitrocellulose strips; the strips were washed as previously described (7) and incubated with unlabeled first antibody and then with iodinated second antibody (ca. 250,000 cpm). The spots were located by autoradiography, cut out, and counted in a gamma counter. The counts were subjected to linear regression analysis, and the slope of the line (counts per minute versus concentration of gD) was calculated.
RESULTS
Comparison of the predicted secondary structures of gD-1 and gD-2. Figure 1 shows a computer representation (7) of the secondary structure of gD-1 (Fig. 1A ) and gD-2 (Fig. 1B) , derived from the predicted amino acid sequences (29, 50, 51) and rules established by Chou and Fasman (5, 6) . It should be noted that these predictive "rules" of secondary structure result in an accuracy of prediction in a three-state model (helix-sheet-turn) of approximately 50 versus 33% for chance (24) . However, in the absence of any additional structural information, we have found that these predictions have heuristic value in that they focus attention on certain regions of the glycoprotein. Furthermore, we have also analyzed both glycoproteins with a second empirical analysis ( Fig. 1 ) which assumes that hydrophilic regions of protein structure have a greater immunological potential (22) . For these calculations, the first 25 amino acids of the predicted sequence were excluded from consideration, since direct Nterminal sequence analysis showed that, for both gD-1 and gD-2, lysine residue 26 of the deduced sequence was the amino terminus of the mature protein (14) . In our numbering system, this lysine is residue 1. The criteria used for predicting the probability of a-turns (7) were modified to increase the likelihood of locating possible epitopes. The modifiedturn criteria predict four additional n-turns in gD-1 at residues 200, 225, 255, and 298. None of these additional turns involves highly hydrophilic regions of the protein. Interestingly, a very hydrophilic region, residues 77 to 95, is not in a predicted a-turn. When the criteria were relaxed even further, this stretch of amino acids was still not predicted to be in a p-turn. The working hypothesis is that epitopes are likely to be located in regions where highly hydrophilic residues are present in ,-turns (45) . If, in addition, the epitope is continuous, synthetic peptides could be used to mimic the reactivity of the epitope. The program has also been expanded to indicate the positions of predicted N-asparagine-linked carbohydrates (shown as balloons) based on the sequence Asn-X-Thr or Asn-X-Ser (23). For gD-1 and gD-2, all three positions are glycosylated (10) . Predictions for hydrophilicity use the same criteria as before (7, 22) . The homology in amino acid sequence is reflected in similarities in both secondary structure and regions of hydrophilicity in the two proteins. In at least one case, however, two differences in amino acid sequence in region 1 to 23 have been correlated with both changes in predicted secondary structure and antigenicity (7, 12, 29, 50, 51) . For both gD-1 and gD-2, there are two regions in which ,-turns intersect a highly hydrophilic region, i.e., residues 11 to 19 and 265 to 282. A third region in gD-1, residues 340 to 356, is hydrophilic and contains a predicted ,-turn overlapping the hydrophilic region. These a-turns are present even when more stringent criteria for predicting turns are applied (7) . In gD-2, however, there is no 3-turn in this region, even with the modified criteria.
Reaction of MCAb in groups I to VII against native and denatured gD. To test the structural predictions, we used the immunoblot assay (7, 20) to determine which of the groups of MCAb reacted with discontinuous or continuous epitopes. Previous studies indicated that only certain MCAb groups reacted with denatured gD (32, 37; J. T. Matthews, G. H. Cohen, and R. J. Eisenberg, unpublished data). Native gD-1 ( . The reaction of native gD-2 with group V was unexpected, since group V failed to immunoprecipitate gD-2 from infected cell extracts (15, 48) . Furthermore, denatured gD-2 reacted either weakly or not at all against group V MCAb, whereas native and denatured gD-1 reacted equally well against the same antibodies. In addition to group V, MCAb in groups II and VII recognized the denatured form of gD-1 and gD-2 (lanes c and d). Thus, three groups of MCAb, II, V, and VII, appeared to recognize continuous epitopes, and four groups of MCAb, I, III, IV, and VI, apparently reacted with discontinuous epitopes that require the native conformation of gD-i (34) .
It should be noted that under the denaturing conditions used considerable secondary and tertiary structure might remain in gD. Therefore, that the protein retained antigenic activity for antibodies in groups II, V, and VII is not proof per se that these epitopes are continuous. In the case of group VII, the proof was provided by the reactivity of a synthetic peptide mimicking residues 8 to 23 of gD-1 against group VII MCAb 170 (7). One of the goals of the present study was to obtain similar proof for the epitopes specified [51] ). First, group V MCAb reacted with fixed, but not with unfixed, HSV-1-infected cells (37) . This suggested that the epitope is not exposed on the external face of the plasma membrane of infected cells. Second, when gD-1 was synthesized and processed in an in vitro system, the processed protein was partially protected from proteolysis by trypsin (37 (22) . The value is therefore distorted at the C-terminal end.
The hexagonal balloons indicate predicted sites (Asn-X-Thr or Ser) of N-asparagine-Iinked glycosylation (23) .
information for the transmembrane-anchoring region plus the carboxy terminus, were cloned into Escherichia coli, the expressed gD-like protein was not recognized by 57S antibody (R. J. Watson, J. H. Weis, J. H. Salstrom, and L. W. Enquist, J. Invest. Dermatol., in press). These results, taken together, suggested that the group V epitope was located between residues 340 and 369 of gD-1.
To localize the epitope further, we relied on the computer predictions ( Fig. 1 and 3) and differences in the sequences of gD-1 and gD-2 at the carboxy terminus (Fig. 3) (29, 50, 51) . We argued that the epitope is largely type 1 specific, based on the immunoprecipitation data (15) , but that certain similarities in sequence might account for the reactivity of gD-2 against group V MCAb in the immunoblot. Region 340 to 356 of gD-1 is highly hydrophilic and contains a predicted j-turn at residues 346 to 349 ( Fig. 1 and 3) . The homologous region of gD-2 is also hydrophilic, but does not contain this predicted turn. In addition, the sequences of gD-1 and gD-2 in the region 340 to 356 (Fig. 3) show similarities (e.g., residues 346 to 349 are Ala-Pro-Lys-Arg and residues 351 to 356 are Arg-Leu-Pro-His-Ileu-Arg in both proteins) and differences (e.g., residues 343 to 345 are Thr-Arg-Lys in gD-1 but are Ala-Gln-Met in gD-2). These differences appear to have a profound effect on the predicted secondary struc- and d) . Two polyclonal sera prepared against gD-1 (rows 1 and 2) reacted with this peptide. In one case (row 1) the reaction was strong, and in the other case the reaction was weak (row 2). In addition, the peptide reacted weakly with one polyclonal serum prepared against purified gD-2 (row 3), but failed to react with a second anti-gD-2 serum (row 4). These results show that (i) the synthetic peptide Localization of the group II epitope. Group II, represented by DL6 MCAb, reacted with the native and denatured forms of both gD-1 and gD-2 (Fig. 2, row 3) , exhibited typecommon membrane immunofluorescence (data not shown), and neutralized HSV-1 at 1:50 dilution and HSV-2 at 1:20, using a 50% endpoint (9, 11) . The continuous epitope recognized by DL6 MCAb was distinct from those recognized by either group VII or V, since DL6 did not react with either the 8-23 [1] or the 340-356 [1] synthetic peptide (Fig. 4, row 6 , lanes c and e). Preliminary localization of the group II epitope was accomplished by testing the reactivity of two truncated forms of gD-1, representing residues 1 to 275 and 1 to 287, against MCAb (Fig. 6 ). Both forms reacted with group VII antibody (row 1, lanes c to e), indicating the presence of residues 8-23 in the truncated proteins. As expected, neither form reacted with group V antibody (row 3, lanes c to e). The truncated form, 1-275 [1] 5, lane d) . Thus, the group II epitope is located between residues 268 and 287 of gD-1. In addition, the peptide reacted against three of the four polyclonal sera prepared against gD (Fig. 4, rows 1 to 3, lane d) .
Peptide 268-287 [1] was coupled to KLH and used to immunize two rabbits. After the initial immunization protocol and one intravenous booster dose, serum samples were assayed for anti-gD and anti-peptide antibodies by the immunoblot assay. Neither serum reacted with native or denatured gD (data not shown). The animals were then given three intravenous booster doses of the free peptide and successive serum samples were assayed again. Again, none of the sera reacted with native or denatured gD. One serum sample reacted with the synthetic peptide 268-287 [1] (data not shown). None of the sera exhibited any neutralizing activity (data not shown).
Localization of discontinuous epitopes of gD-1. Previously, we developed a procedure (15) to partially fragment gD, using S. aureus protease V8, an enzyme which cleaves specifically at glutamic acid residues. In that procedure, metabolically labeled gD was immunoprecipitated with a MCAb plus S. aureus-bearing protein A and the complex was treated with the protease (15) . The antibody protected that portion of gD to which it was bound, and the bound and unbound fragments were characterized by SDS-PAGE and tryptic peptide analysis. We found that group I, IV, and VI MCAb remained bound to a 38K fragment which, on the basis of N-terminal amino acid sequencing (14; D. Long, G. H. Cohen, R. Hogue-Angeletti, and R. J. Eisenberg, unpublished data), was found to contain the amino terminus of pgD (the precursor form of gD). Analysis of the tryptic glycopeptides (10) of the 38K fragment showed that glycopeptides 1 and 2 were present but that glycopeptide 3 Figure 2 (lane e) shows that group I, III, IV, VI, and VII MCAb bound to another truncated form of gD-1 consisting of residues 1 to 275 (30) . These results agree with those of V8 proteolysis (15) with the exception of group III (11S). One possibility was that the group III epitope included residues between 260 and 275. Another possibility is that binding of group III occurred within the 38K fragment, but that this binding did not protect the fragment frorn further proteolysis (15) . To determine directly whether group III MCAb could bind to the 38K fragment, we carried out the following experiment. A group I MCAb (HD-1) immunosorbant was used to bind purified gD-1. This complex was washed extensively, and a portion was treated with S. aureus protease V8 and washed again. Then various iodinated MCAb were added, and the complex was washed extensively and then counted in a gamma counter. Table 1 shows that, in the HD-1 control (HD-1 as immunosorbant and iodinated probe), no significant counts bound above background in either the V8-treated or the untreated sample. We also probed the V8-treated and untreated samples with group V antibody (57S) and found that the untreated sample contained a significant number of counts and the V8-treated sample contained no counts above background. This indicated that the proteolysis was complete and that the group V epitope was not present after V8 treatment. With iodinated 11S (group III MCAb) as the probe, approximately the same number of counts bound to the V8-treated and untreated gD-1-HD-1 complexes. These results show that the group III epitope is present on the 38K fragment and, furthermore, that this epitope is distinct from the group I epitope.
Topographical relationship of epitopes located in residues 1 to 287 of gD-1. Previous experiments indicated that six epitopes of gD-1 were located within the first 287 residues of the protein, two of which were continuous and four of which were discontinuous. Two different experiments were carried out to begin to define the relative positions of these epitopes. These will be referred to as competition experiments, although we recognize that the term does not accurately describe the type of analysis being performed. First, representative MCAb from the six groups were covalently bound to Sepharose. A preliminary experiment was carried out to determine the amount of each immunosorbant required to bind a given amount of gD-1 present in infected cell extracts. The appropriate amount of each immunosorbant was used to bind similar amounts of unlabeled gD-1. After this, a different and iodinated second antibody was added, and the complexes were washed extensively and counted in a gamma counter. The underlined values in Table 2 show that each antibody group competed against itself, since only background levels of counts bound when the same antibody was used as immunosorbant and iodinated probe. Three types of results were obtained: (i) no competition, in which a significant number of counts were bound, e.g., using group III as immunosorbant and group I as probe, or vice versa; (ii) complete competition, in which only a background number of counts were bound, e.g., J. VIROL. comparing group IV against group III; (iii) partial competition, in which some counts were bound, e.g., comparing group VI and group I. In this assay, there is no way to know what the maximal level of binding should be.
As a second approach (Table 3) , different concentrations of purified gD-1 were spotted onto nitrocellulose strips which were then incubated with an excess of unlabeled antibody. The strips were washed and incubated with iodinated second antibody. The maximal level of binding (no competition or 0% in Table 3 ) was determined from a control in which the strip was incubated only with labeled antibody. The values underlined in Table 3 represent the percent competition which occurred when the same antibody, both unlabeled and labeled, was used to compete against itself. Theoretically, these value should approach 100%. For group II, this value was 93%; however, for groups I and III, the value was 70%. The reason for this is not understood, since, in each case, the first antibody was presumably present in excess. It may be a problem of antibody affinity or presentation of the antigen on nitrocellulose. Nevertheless, when heterologous antibody groups were compared, the results agreed with the results in Table 2 . There was no competition between groups I and III or I and VII. Furthermore, there was partial competition between groups I and IV and I and VI. Group III showed partial competition with groups IV and VI. Group II MCAb showed slight competition with group VI and possibly group I. Thus, the two kinds of experiments lead to the same conclusions and form the basis for topographical positioning of these epitopes in gD-1 (Fig.  7) .
DISCUSSION
In previous studies, we defined eight antigenic epitopes of gD, based on an analysis with a panel of MCAb (15) . We attempted to associate the binding of particular MCAb with different fragments of the protein and found that several of them were in a 38K fragment which encompasses the amino terminus. We further defined the position of one continuous epitope of gD, amino acid residues 11 to 19, which reacts with group VII MCAb (7, 12) . Localization of that epitope was based on the V8 proteolysis studies (15) pared against gD, including an antiserum prepared against gD-2. More recently, we have tested additional polyclonal sera prepared in rabbits against gD-1 and gD-2 and have found that six of eight sera, including two prepared against gD-2, reacted with this peptide. In addition, antiserum prepared to the peptide reacted with gD-1 and gD-2 in immunoblot and immunoprecipitation assays, although the reaction was much stronger against gD-1. A somewhat puzzling observation was that this antiserum was more reactive against the native than the denatured forms of gD-1 and gD-2 (Fig. 5A, lanes a to d) Another puzzling observation was the reactivity of group V MCAb against gD-2 detected by immunoblot. Previously, these antibodies were considered type 1 specific based on immunoprecipitation and immunofluorescence assays. Although most of the amino acids in the epitope specified by group V antibodies may be unique to gD-1, it is clear from examination of the sequence in this region that several amino acids in the epitope must be common to gD-1 and gD-2. The more sensitive immunoblot assay might better detect this partial overlap. Alternatively, gD-2 might assume different conformations under the conditions used in different assays (27, 38) . The few type common residues in this sequence may be arranged close together in the native gD's, so that a weak type common reactivity can be seen, although the sequences otherwise differ substantially. If so, it would explain why group V MCAb appeared to be more reactive against native than against denatured gD-2 (Fig. 2, row 6,  lanes b and d) . Fine mapping of the group V epitope should take into account the differences in sequence between gD-1 and gD-2 in this region.
Localization of the group II epitope was accomplished first by analyzing the reactivity of truncated forms of gD-1 against DL6 MCAb. The antibody failed to react with a truncated form of gD ending at residue 275 of the mature protein (30) but did react with a form of gD ending at residue 287 (M. G. Gibson and P. G. Spear, in press ). These results suggested that the epitope was between residues 275 and 287. The computer predictions (Fig. 1) showed that gD-1 and gD-2 each contained a region with hydrophilic residues within a P-turn. Interestingly, this region is rich in acidic residues (both aspartic and glutamic acids) and proline, but lacks the basic amino acids, such as lysine, that are often associated with epitopes (31) . In choosing a synthetic peptide for confirmation of the location, we assumed that the epitope could include some residues upstream of 275. Peptide 268-287 [1] reacted with DL6 MCAb and with three polyclonal sera prepared against gD. This peptide also reacted with several other polyclonal anti-gD rabbit sera, a total of four to gD-1 and two to gD-2. However, when rabbits were immunized with this peptide coupled to KLH, there was no antibody response. After several injections with the free peptide, one of the sera exhibited reactivity against the peptide but not against gD. In this case, it is possible that none of the conformations of the peptide coupled to KLH corresponded to the structure of the peptide as it is found in native or denatured gD.
The synthetic peptide approach we took in these studies is not yet likely to be fruitful in localizing discontinuous epitopes (1, 45) . This is because these epitopes depend on a certain tertiary structure of gD, which in part involves disulfide bonds. The position of these bonds is not yet known, but such information should aid in localization. However, we do know that four discontinuous epitopes of gD-1 are located within the first 260 amino acids of the protein (Fig. 7) , since antibodies in groups I, III, IV, and VI reacted with truncated gD-1 (1 to 275) as well as with the 38K fragment (presumably residues 1 to 260) generated by V8 proteolysis. Six of the seven cysteine residues of gD-1 are located within residues 66 to 202. It is quite possible that disulfide bonds formed by these six cysteines play a role in the structure of discontinuous epitopes. Cysteine at residue 333 of the mature protein is within the transmembrane region of gD-1 and is not involved in formation of these epitopes. Thus, our data predict that this cysteine is probably not involved in intramolecular disulfide bonds in gD-1. However, it may be involved in intermolecular disulfides, perhaps in formation of the gD-1 dimer (17, 18) . In this regard, it is interesting to note that gD-2, which lacks this cysteine, does not form dimers (17, 18) . In preliminary experiments, we have found that the group III epitope is destroyed by boiling gD-1 in SDS in the absence of mercaptoethanol, whereas destruction of groups I, IV, and VI required reduction and alkylation (M. Ponce de Leon, G. H. Cohen, and R. J. Eisenberg, unpublished data).
Competition experiments were carried out to determine the relative orientation of the four discontinuous epitopes. In some cases, the binding of one antibody to gD-1 had no effect (no competition) on the binding of another. These results are further evidence that the MCAb groupings are valid and that there are distinct discontinuous epitopes on gD-1. In other cases, there was competition. This indicated that (i) some amino acids in these epitopes are shared; or (ii) the epitopes were so close that there was steric hindrance in the binding of a second antibody; or (iii) binding of one antibody altered the conformation of gD so that binding of the second antibody was affected (35) . Previously, we speculated that binding of group III MCAb altered the conformation of gD-1, making the molecule more susceptible to protease V8 cleavage (15) . This explanation is still consistent with the present results.
On the basis of these studies, as well as the studies of three continuous epitopes, we have constructed a two-part topographic map for gD-1 (Fig. 7) Fig. 7) , although we do not know how many cysteines are disulfide bonded in gD or how many are involved in determining the structure of any one epitope.
Further localization of discontinuous epitopes will require other approaches, including a more complete understanding of the contribution of disulfide bonds to the structure of gD.
One possible approach will be to analyze the amino acid changes associated with mutants which exhibit an altered pattern of reactivity with MCAb. Such mutants would include those which are no longer neutralized by antibody, such as the "mar" mutants (21) . Another approach would be to examine the amino acid changes found in natural isolates of HSV which exhibit an anomalous pattern of reactivity with MCAb (41, 43) . This approach was recently exploited (43) to explain the reactivity of an HSV-1 strain with a gD-2-specific MCAb called 17f3A3 (2) . Analysis of the DNA sequence of the gD gene of the isolate revealed a change which altered the codon for asparagine (residue 72 of the mature protein) present in the prototype HSV-1 strain to histidine, normally present in the HSV-2 strain. Grouping of 17,A3 has not yet been accomplished. However, it might be in group VIII (15) . Our uncertainty about the grouping of 17,A3 illustrates the need for a common classification of gD-specific MCAb. We are now in the process of grouping a number of additional gD-specific MCAb from several laboratories to overcome this difficulty.
